{"name":"Ventrus Biosciences, Inc","slug":"ventrus-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Diltiazem Hydrochloride 2% Cream","genericName":"Diltiazem Hydrochloride 2% Cream","slug":"diltiazem-hydrochloride-2-cream","indication":"Anal fissure pain relief (topical)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"VEN 307","genericName":"VEN 307","slug":"ven-307","indication":"Open-angle glaucoma","status":"phase_3"}]}],"pipeline":[{"name":"Diltiazem Hydrochloride 2% Cream","genericName":"Diltiazem Hydrochloride 2% Cream","slug":"diltiazem-hydrochloride-2-cream","phase":"phase_3","mechanism":"Diltiazem is a calcium channel blocker that reduces smooth muscle contraction and improves blood flow when applied topically to affected tissues.","indications":["Anal fissure pain relief (topical)"],"catalyst":""},{"name":"VEN 307","genericName":"VEN 307","slug":"ven-307","phase":"phase_3","mechanism":"VEN 307 is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma by enhancing aqueous humor outflow.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQWGxPTnZ1NEtpdVRFNTdpdW5PTnZlX2hVaDZSMHhjQVRqbUlqU3JzTnlHT214RU9ZZXVGUXBDQW84aTZSZ3ktOERyMHUtdFViakRiMFBtZjY3WXhPQnlUUUtFRVdKRFhDRnR1bnkzdC1nZzA0dUxlWG10TFNPTTRvQmN0N2V2NkJ3QVZOVDRhVk85TGFjR29MZHJ0S1FSRXE3MGZzNWVqUk9GdjhWRmtNSw?oc=5","date":"2026-01-08","type":"pipeline","source":"MedCity News","summary":"Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition - MedCity News","headline":"Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNNF8yRVVRdmFIVnN4aUFZOXpLSzhrUU1nZE1Wd241MllMMldSMVROMmduVHJKa1lEZS1kMFQ3MTIzcXhBTVVOR1RCSGZWRk1ZMXFraTRZTmNYODc1dEY4VGdUelUxM0pnWWVwd09LaHpOd0xOUGd3OWZ4eV9JODNWYnVUd1ZkMkZleGd3?oc=5","date":"2025-12-31","type":"pipeline","source":"The Business Journals","summary":"More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals","headline":"More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iVUFUYkF6aGt3akxZT0hGaW1LLTVITDlQdFFCYUZkc2IwaDJKSHZpQ1d2VmtPWldraV9yWm9idUZab0xqcWZzdXllQ1BIaF9WUGVxcFJMNWhPakFld2QzRVg2dElTbkZjVjdzcEY3QmtFRG96SzhTT25aMkY?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZU50WWp1c0VZbS1ndGwtMmVIQUV4U0Y2cmpVaUU4X3F3U0U4Y3dzd2l6UFRkWmRFbGJjdHRDT3hhQU5kQTFsdi1uMWkxT2haRThaRXlfUUkweU9ERDRFMzVOOVFiMFpCc3NFVnpNZU50RGxEcHNHaW5VQnVHSmlSWmFLU1g4T3NQV0gza1BBbXNHcGwzVkNlVFk4N3V5cE5GOTRxT3R4LURRZkE1SnlWVDFjWklhLUh1VzVUdHJRdUdTUQ?oc=5","date":"2025-10-23","type":"trial","source":"MedCity News","summary":"Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set Up Talks With a Big Pharma Firm - MedCity News","headline":"Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set Up Talks With a Big Pharma Firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNVmpBNXpaUTlxRnNzaWhDMnVzSEplQTZsNEtiVHpyUlYtU0JJVVlKVGw0dWxwbldGdEJlbjN1MnlfV0FOSzZxRmZNMlFiUGZLNUowaUxISkNnSkhSVkdYWjd0WGJ6X3BBdmtuS2EtaFNwRmxEaVRnTkw4Rk5nSUt1MEppYnBHUm1HYkpEMzZyVGEwMlVUSHlkTUVpWQ?oc=5","date":"2025-10-21","type":"deal","source":"Contract Pharma","summary":"Ventus Therapeutics & Genentech Enter Collaboration - Contract Pharma","headline":"Ventus Therapeutics & Genentech Enter Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxONkNsZzBVYzVOUjI5cFdOMFJESUVSbG1FWWRFMUNYVzAtcEtkUk52Xzk1cG94a0E2M0pjNU5kMTlEdlpYSjhiMldmdG1BSzJRRlVMdjA4MGJoR1k4REtZNVpYMDhhdkZNaVpNVXZ3Ylo2ZXZXWEVWY1lQMGctcFBWS0piSllqa0plR3ZMcE9rX01tbF9R?oc=5","date":"2025-02-21","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—NIH leaders join health agency exodus - Fierce Biotech","headline":"Chutes & Ladders—NIH leaders join health agency exodus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNR3JCQnhRWFJKakk0Ykwxd25Za2xkR2lvY1ZPbGNUR29BaDZiaHZ5TWRZbmxUUm9RaXNPWFNjaFduVUw5NHBZRmZWQ01KYnUwNlVlRzg3UFVZcWJ4eFpzNHk1VGZLNDd4OWwzUllQRkIyZFNsVzB5UDBNd3Q3OGFMQllCR2NDczdtaXhETmhhM0swQ2oxT1NRRnlvdkRQbzRGLWFJX3BqTXRXcHQya3ctdFJEYlc0YlAwdFo0bW1TMFNTQUhSb01scmI2SFYwN3RISDhRUU9yazBLWklLMU9nbEJINGdaa3QtdTh3d0dYdHVnY3R1b2FEZDFWcGk2YkdqX25yOVVNUC1xOVRVWDVKcl80NGgwc0ZwZW9MLUJLYjFmWkl6T1NOT1hXQ1h4eVlNNTVLVU9pWDB4bFBLVUdiSEMzT0wyZ0ZVMERyTmdYanlXWGhwbGc?oc=5","date":"2024-11-13","type":"trial","source":"GlobeNewswire","summary":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears - GlobeNewswire","headline":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5KYWltUm5DS0RXdklEaGJOdkhEd0kzcU5DNTNsdVhXMkQ2Q0VSaW55OGY5OWxSSHdoTlVsUnVicHNzWE9UM1lJRXhhY09xU3RhMmFQeTZRM2tuZE5jUkM4V2FDQjlQUWMyN1VNalFjbjVZOG45SHdGVTd6a3A?oc=5","date":"2023-08-28","type":"pipeline","source":"Fierce Biotech","summary":"Introducing Fierce Biotech's 2023 Fierce 15 - Fierce Biotech","headline":"Introducing Fierce Biotech's 2023 Fierce 15","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQdUlJOW5QYTVJYXdUUUh1dTFDTmZHb2lJbU56Ul9MUllUSnRLVDVfNFZ1NXUzYXY3Y05QMk9kcVI1V3czbHRFd3BsUkI3WkFmV1kyaTB6SFh1UVdBY1pvMjd2Mmlxa2JoT1QyODBDYlJ6SDZTOWo4Zks4M1ZHZk9LRGM5UC1CMXpjR2IxVnhIcw?oc=5","date":"2022-09-29","type":"pipeline","source":"BioPharma Dive","summary":"Ventus sells its lead drug candidate to Novo Nordisk - BioPharma Dive","headline":"Ventus sells its lead drug candidate to Novo Nordisk","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}